The Business Times
The Business Times
Subscribe
Share on FacebookShare on TwitterView more
The Business Times
Create a free account with Business Times for seamless access across SPH Media products.
REGISTER
LOGIN

Companies & Markets

SUBSCRIBERS

Shire to buy rare-disease drugmaker NPS Pharmaceuticals for US$5.2b

Deal comes before NPS learns whether its Natpara medicine to treat hypoparathyroidism wins approval from the US FDA

Published Mon, Jan 12, 2015 · 09:50 PM
Share this article.

London

SHIRE plc, the drugmaker seeking to boost growth after its proposed sale to AbbVie Inc collapsed, agreed to buy NPS Pharmaceuticals Inc for about US$5.2 billion to add medicines used to treat rare diseases.

Shire will pay US$46 a share in cash, the Dublin-based company said on Sunday in a statement. That's a 9.8 per cent premium to NPS's closing price on Jan 9 and more than 50 per cent higher than its close on Dec 16, before news broke of Shire's interest. The deal has been approved by both companies' boards.

Adding Bedminster, New Jersey-based NPS will enable Shire to expand in rare diseases such as gastrointest…

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to  t.me/BizTimes

Consumer & Healthcare

SUPPORT SOUTH-EAST ASIA'S LEADING FINANCIAL DAILY

Get the latest coverage and full access to all BT premium content.

SUBSCRIBE NOW

Browse corporate subscription here